News

The National Hemophilia Foundation (NHF) and Takeda have teamed up to launch a series of PSAs and resources that hope to increase…

At the National Hemophilia Foundation’s (NHF) Bleeding Disorders Conference, held virtually this year, NHF president and CEO Leonard Valentino, MD, asked each…

A paper published in the journal Haemophilia, suggests that clinical expectations for people with hemophilia have remained relatively static for years, falling…

It is well established that the clinical management of pregnant women with congenital bleeding disorders (CBDs) is challenging, as healthcare providers, including…

Immediately following the issuance of medical advisories to the community regarding the recall of Stimate® (desmopressin nasal spray ) a product used to control…

Ferring Pharmaceuticals Inc. is initiating a precautionary voluntary recall of all batches of Stimate® Nasal Spray (desmopressin acetate) 1.5 mg/mL. During testing…

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the second interim analysis of the…

The Partners in Bleeding Disorders Education Program has announced the launch of a new online learning module, “Accounting for Home Care: The Role…

CSL Behring recently announced that it has agreed to acquire exclusive global license rights from uniQure, to commercialize etranacogene dezaparvovec (AMT-061), an…

Sanofi and Sobi, along with the World Federation of Hemophilia (WFH) and WFH USA recently announced as extension of the two companies’…

The Partners in Bleeding Disorders Education Program has announced the launch of two new online learning modules that speak to the history of…

BioMarin has released updates on the ongoing clinical trial program for their investigational gene therapy valoctocogene roxaparvovec, which is intended for the…

Findings from an international study published in the journal Medicine suggest that the visible presence of blood in urine (macroscopic hematuria) could represent increased…

Letter of Intent Deadline: July, 5, 2020 Application Deadline: August 16, 2020 Award Start Date: December 2020   NHF’s premier research fellowship program is named in…

These continuing education activities are intended for hematologists, pediatricians, and other healthcare professionals who manage patients with hemophilia. The National Hemophilia Foundation…

A paper published in the journal Haemophilia, suggests that clinical expectations for people with hemophilia have remained relatively static for years, falling out…

To all physicians, hematologists, and other healthcare professionals It has become apparent in the recent weeks that COVID-19 patients with severe disease…

Dear Community Members, The National Hemophilia Foundation wishes to inspire and partner with the community on their journeys to a cure and…

UniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, reported recent progress across its business. “Despite…

Pfizer Inc. and BionTech SE announced the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for…

Findings from an international study published in the journal Medicine suggest that the visible presence of blood in urine (macroscopic hematuria) could represent increased…

Dear Community Members, The National Hemophilia Foundation’s priority has always been the health and safety of the bleeding disorders community. As the…

The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) are seeking comments from the bleeding disorders community on the executive summary…

Genentech recently distributed a notice relevant to its product Hemlibra®, reminding health care providers that it is known to interfere with certain laboratory assays used to…